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Abstract
Background: Recent reports have questioned the efficacy of intraosseous (IO) drug administration for out-of-hospital cardiac arrest (OHCA)
resuscitation. Our aim was to determine whether prehospital administration of resuscitative medications via the IO route was associated with lower rates
of return of spontaneous circulation (ROSC) and survival to hospital discharge than peripheral intravenous (IV) infusion in the setting of OHCA.
Methods: We obtained data on all OHCA patients receiving prehospital IV or IO drug administration from the three most populous counties in Michigan
over three years. Data was from the Michigan Cardiac Arrest Registry to Enhance Survival (CARES) database. The association between route of drug
administration and outcomes was tested using a matched propensity score analysis.
Results: From a total of 10,626 OHCA patients, 6869 received parenteral drugs during their prehospital resuscitation (37.8% by IO) and were included in
analysis. Unadjusted outcomes were lower in patients with IO vs. IV access: 18.3% vs. 23.8% for ROSC (p < 0.001), 3.2% vs. 7.6% for survival to
hospital discharge (p < 0.001), and 2.0% vs. 5.8% for favorable neurological function (p < 0.001). After adjustment, IO route remained associated with
lower odds of sustained ROSC (OR 0.72, 95% CI 0.63 0.81, p < 0.001), hospital survival (OR 0.48, 95% CI 0.37 0.62, p < 0.001), and favorable
neurological outcomes (OR 0.42, 95% CI 0.30 0.57, p < 0.001).
Conclusion: In this cohort of OHCA patients, the use of prehospital IO drug administration was associated with unfavorable clinical outcomes.
Keywords: Out-of-hospital cardiac arrest, Intraosseous drug administration, Cardiopulmonary resuscitation

Introduction
Outcomes following out-of-hospital cardiac arrest (OHCA) remain
poor, with only 7.6% 12% of patients surviving to hospital

discharge nationally.1,2 While high-quality cardiopulmonary resuscitation (CPR) is the mainstay of initial treatment, guidelinebased care also includes the delivery of medications such as
epinephrine and amiodarone. Despite conflicting data in the
literature to support some pharmacological therapy in OHCA to
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improve patient outcomes,3,4 the standard of care established by
the American Heart Association (AHA) Advanced Cardiac Life
Support (ACLS) guidelines recommend establishing either intravenous (IV) or intraosseous (IO) access for pharmacological therapy
during cardiac arrest.5 Traditionally there has not been a distinction
between IV and IO access with respect to efficacy of drug delivery.
Emergency medical services (EMS) guidelines vary between
regions, resulting in varied practice patterns. Some providers
may commonly utilize IO cannulation as the initial access; others
may only use it as a last resort. Given its ease of use and high rate of
placement success, however, IO access has become increasingly
common in the pre-hospital setting.6 9
Although IO infusion is well-established as an effective route
for the prehospital resuscitation of trauma, pediatric and shock
patients,10,11 its efficacy in cardiac arrest resuscitation has
recently been called into question. 12 15 The purpose of this study
was to compare OHCA clinical outcomes according to IO or IV
route of drug administration using data obtained from the
Michigan Cardiac Arrest Registry to Enhance Survival (CARES)
database.

XXX

Methods
Study hypothesis
The study hypothesis was that the rates of return of spontaneous
circulation (ROSC), survival to hospital discharge, and favorable
neurological survival (defined as a cerebral performance category
score of 1 or 2 at hospital discharge) were worse in patients receiving
prehospital drug delivery through IO access than IV access.

Study design, setting, and population
The CARES database is a prospective, multicenter registry of patients
with OHCA in the United States. The Centers for Disease Control and
Emory University established CARES for cardiac arrest surveillance
and quality improvement activities. Prior publications describe the
design for the registry.16,17 In brief, CARES captures OHCA patients
for whom an emergency medical services (EMS) provider attempts
resuscitation. Throughout the United States, more than 1400 EMS

Table 1 – Baseline demographics of out-of-hospital cardiac arrest patients.

Characteristics
Age in years (Mean  SD)
Sex n (%)
Female
Male
Race n (%)
African American
White
Other/unknown
Medical problems n (%)
Cancer
Diabetes
Heart disease
Hypertension
Hyperlipidemia
Pulmonary disease
Renal disease
History of stroke
First rhythm type n (%)
Non-shockable
VF/pVT
Bystander CPR n (%)
Arrest location n (%)
Home
Assisted living
Public
Incident county n (%)
Macomb
Oakland
Wayne
Targeted temperature management n (%)
Witnessed arrest n (%)
Naloxone given n (%)
Epinephrine given n (%)
First responder present n (%)
Endotracheal tube placed n (%)

All patients

IO Access

IV Access

IO vs IV

N = 6896
64.8  18.1

N = 2603
65.2  17.9

N = 4293
64.5  18.2

P-value
0.13

2754 (39.9)
4142 (60.1)

1155 (44.4)
1448 (55.6)

1599 (37.2)
2694 (62.8)

<0.0001

1525 (22.1)
3350 (48.6)
2021 (29.3)

580 (22.3)
1279 (49.1)
744 (28.6)

945 (22.0)
2071 (48.2)
1277 (29.7)

0.59

362 (5.2)
996 (14.4)
1293 (18.8)
1290 (18.7)
153 (2.2)
656 (9.5)
410 (5.9)
215 (3.1)

114 (4.4)
347 (13.3)
483 (18.6)
459 (17.6)
50 (1.9)
251 (9.6)
137 (5.3)
68 (2.6)

248 (5.8)
649 (15.1)
810 (18.9)
831 (19.4)
103 (2.4)
405 (9.4)
273 (6.4)
147 (3.4)

0.038
0.097
0.95
0.16
0.42
0.95
0.17
0.17

5739 (83.2)
1157 (16.8)
2483 (36.0)

2278 (87.5)
325 (12.5)
1033 (39.7)

3461 (80.6)
832 (19.4)
1450 (33.8)

<0.0001

4728 (68.6)
1231 (17.9)
937 (13.6)

1696 (65.2)
587 (22.6)
320 (12.3)

3032 (70.6)
644 (15.0)
617 (14.4)

<0.0001

1640 (23.8)
1988 (28.8)
3268 (47.4)
683 (9.9)
3102 (45.0)
1337 (19.4)
6780 (98.3)
1394 (20.2)
2857 (41.4)

605 (23.2)
784 (30.1)
1214 (46.6)
199 (7.6)
1102 (42.3)
505 (19.4)
2597 (99.8)
522 (20.1)
1013 (38.9)

1035 (24.1)
1204 (28.0)
2054 (47.8)
484 (11.3)
2000 (46.6)
832 (19.4)
4183 (97.4)
872 (20.3)
1844 (43.0)

0.18

<0.0001

<0.0001
0.0006
0.98
0.45
0.80
0.0010

IO = intraosseous, IV = intravenous, VF = ventricular fibrillation, pVT = pulseless ventricular tachycardia, CPR = cardiopulmonary resuscitation.
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systems provide data to CARES. CARES also incorporates data from
911 dispatch centers and receiving hospitals and uses standardized
international Utstein definitions for clinical variables and outcomes.18
After securing Institutional Review Board (IRB) approval, deidentified data were obtained in collaboration with SaveMIheart
(Michigan) from the CARES database on all nontraumatic OHCA
patients age 18 years from the three most populous counties in
Michigan (Wayne, Oakland, and Macomb). The dates of patient
inclusion were January 1, 2015 through December 31, 2017. Patients
who did not receive drug delivery through either IO or IV access were
excluded from the study. Although CARES data collection did not
include the site of IO placement, review of EMS agency protocols in
the included counties confirmed that proximal tibial placement was
designated in all protocols. Additionally, these EMS agency protocols
provide medics with the option to use either IO or IV access as first line
access rather than protocolizing IO as being first or second line for
access.19,20 Data on number of attempts for access or time-to-access
was not available.
The CARES registry collects patient-level EMS data on patient
demographics and clinical characteristics, geographic location of
cardiac arrest, presenting cardiac rhythm, presence of a witness,
bystander CPR, route of vascular access, timing of arrest to EMS
arrival, time to death or return of spontaneous circulation (ROSC),
transportation time, medication administration, and interventions.
Data collected from destination hospitals includes survival to hospital
admission, survival to hospital discharge, and neurological survival.
Favorable neurological survival is defined as survival to hospital
discharge with a cerebral performance category (CPC) score of 1
(mild to no neurological disability) or 2 (moderate neurological
disability).18

Outcomes
The primary outcome was survival to hospital discharge. Secondary
outcomes included sustained ROSC and survival to hospital
discharge with favorable neurological recovery.

Statistical analysis
We present demographic data with mean (standard deviation) or
median (interquartile range) for continuous variables, or frequency
(percentage) for categorical variables. Demographic data for patients
with IO and IV access were compared using chi-square tests for
categorical variables and a t-test or Wilcoxon Mann Whitney test for
continuous variables.
To account for the non-random selection of access route, we
performed a matched propensity-score analysis, which accounted for
age, sex, initial cardiac rhythm, witnessed status, bystander CPR,
location and history of cancer.14 Logistic regression models were
used to examine the relationship between attempted access (IO or IV)
and survival to discharge, return of spontaneous circulation (ROSC),
and good neurological recovery after adjusting for age, sex, race,
initial cardiac rhythm, bystander CPR, location, incident county,
witnessed status, use of targeted temperature management, naloxone administration, first responder presence, endotracheal intubation
and comorbidities. Patients were matched 1-to-1 on their propensity
score with a caliper width of no more than 0.2 times the standard
deviation of the logit of the propensity score. Conditional logistic
regression adjusting for these variables above was performed. All
analyses were performed using Statistical Analysis System (SAS

3
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Institute Inc., Cary, NC). A p-value < 0.05 was considered statistically
significant.

Results
We identified 10,887 patients in the CARES database in the included
counties over the study period, with the final study population
consisting of 6896 patients who received either IO or IV access for
drug delivery. Intraosseous access was placed in 2603 (37.7%)
patients and IV access in 4293 (62.3%) patients. Comparative
demographic and clinical characteristics of OHCA patients based on
IO versus IV access are shown in Table 1. There were higher
proportions of females and higher rates of non-shockable rhythms in
patients receiving IO access. Patients receiving IV access had a
higher rate of witnessed arrest. Reported comorbid conditions were
similar between the IO and the IV groups, except for cancer. The
proportion of patients receiving epinephrine was similar in each group.
There were less than 20 patients total in each group receiving other
medications including amiodarone, dextrose, bicarbonate, or calcium.
Table 2 compares baseline demographics after propensity matching.
Table 3 shows the unadjusted association between IO and survival
outcomes of sustained ROSC, survival to hospital discharge, and
favorable neurological outcome. The unadjusted rate of survival to
hospital discharge was lower in patients receiving IO access
compared with IV access (3.2% versus 7.6%, p = 0.001). After
multivariable adjustment and propensity score matching, IO access
continued to be significantly associated with decreased survival
(adjusted OR 0.51, 95% CI 0.40 0.67), as well as ROSC (adjusted
OR 0.75, 95% CI 0.66 0.85) and good neurological function (adjusted
OR 0.44, 95% CI 0.32 0.61). As seen in Table 3, the odds ratios were
nearly identical with propensity score matching.
Time from EMS dispatch to arrival on scene was available in 2639
patients. Repeating the multivariable analysis using only patients with
time from EMS dispatch to scene arrival data, there remained a
significant association with reduced odds of survival to hospital
discharge (OR 0.43, 95% CI 0.27 0.68) and good neurological
function (OR 0.53, 95% CI 0.32 0.88) with IO compared to IV access.

Table 2 – Baseline demographics of out-of-hospital
cardiac arrest patients after propensity score
matching.

Characteristics
Age in years (Mean  SD)
Sex n (%)
Female
Male
First rhythm type n (%)
Non-shockable
VF/pVT
Witnessed arrest n (%)
Bystander CPR n (%)
Public location n (%)
Cancer* n (%)

IO Access

IV Access

IO vs IV

N = 2597
65.3  17.8

N = 2597
65.3  18.0

P-value
0.97

1149 (44.2)
1448 (55.8)

1160(44.7)
1437 (55.3)

0.76

2272 (87.5)
325 (12.5)
1102 (42.4)
1027 (39.5)
320 (12.3)
114 (4.4)

2266 (87.3)
331 (12.7)
1127 (43.4)
1012 (39.0)
306 (11.8)
102 (3.9)

0.80
0.48
0.67
0.55
0.70

IO = intraosseous, IV = intravenous, VF = ventricular fibrillation, pVT = pulseless
ventricular tachycardia, CPR = cardiopulmonary resuscitation.
*
Past history of cancer was included in propensity score matching due to
significant difference in incidence of cancer among the IO and IV groups.
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Table 3 – Outcomes of patients with out-of-hospital cardiac arrest receiving either IO or IV access, after
multivariable adjustment (3A) and propensity score matching (3B).

3A. Primary study cohort (N = 6896)
ROSC n (%)
Survival to hospital discharge n (%)
Good neurological function n (%)
3B. Propensity score matched cohort
ROSC n (%)
Survival to hospital discharge n (%)
Good neurological function n (%)

IO Access

IV Access

Adjusted OR

475 (18.3)
84 (3.2)
51 (2.0)
IO Access
(N = 2597)
475 (18.3)
84 (3.2)
51 (2.0)

1023 (23.8)
328 (7.6)
247 (5.8)
IV Access
(N = 2597)
599 (23.1)
168 (6.5)
119 (4.6)

0.75 (0.66 0.85)
0.51 (0.40 0.67)
0.44 (0.32 0.61)

<0.001
<0.001
<0.001

0.78 (0.67 0.90)
0.50 (0.37 0.66)
0.42 (0.30 0.60)

<0.001
<0.001
<0.001

p-Value

IO = intraosseous, IV = intravenous, OR = odds ratio, ROSC = return of spontaneous circulation.

The association with IO access and ROSC was not statistically
significant (OR 0.85, 95% CI 0.69 1.05), when taking into consideration time from EMS dispatch to arrival.

Discussion
Our study includes a large cohort of OHCA patients, in which a
significant proportion (37.7%) received medications via the tibial IO
route. After propensity matching and adjustment for many confounding variables, intraosseous access was negatively associated with
return of spontaneous circulation, survival to hospital discharge, and
favorable neurological outcome.
Given increasing popularity of IO access, our study, along with a
growing body of literature, highlights the urgent need for prospective
studies to evaluate the efficacy of IO drug delivery in OHCA
resuscitation. Feinstein et al. demonstrated decreased rates of
ROSC associated with IO drug delivery but no difference in survival to
hospital discharge.11 Kawano et al. showed decreased rates of
ROSC, survival to hospital discharge, and favorable neurological
outcome in patients receiving IO access.13 In this study, only 5% of the
cohort received IO access, and receiving IO access could have been
secondary to characteristics predictive of difficult IV access, thus
altering outcomes.
Mody et al. also recently demonstrated a reduction in sustained
ROSC associated with IO access but no change in survival to hospital
discharge or neurological outcomes.14 Their analysis included a large
data set of patients across multiple sites in North America, which
increases the generalizability of these findings. Clemency et al
showed no significant difference in ROSC between patients receiving
IO or IV access. In this study, 39.9% of patients received IO access as
the first route for parental drug administration.15 Finally, Daya et al.
evaluated the efficacy of amiodarone and lidocaine stratified by route
of drug delivery in the Resuscitation Outcomes Consortium
Amiodarone, Lidocaine or Placebo Study. In this population of
3019 patients with ventricular fibrillation or pulseless ventricular
tachycardia, increased survival to hospital discharge was associated
with the intravenous route of drug administration.21
More recently, a prospective cluster-randomized study evaluated
outcomes in OHCA patients receiving IV versus IO prehospital
medications.22 In this study, OHCA patients were randomly assigned
to an IV access group or an IV + IO group in which IO access was
attempted after two failed IV attempts or after 2 min (whichever came
first). In this study, patients in the IV + IO group had a shorter time to

vascular access and to epinephrine administration than the IV group.
However, there was no difference in the rate of ROSC, survival to
hospital discharge or good neurological outcome between the two
groups despite prior studies demonstrating a potential for improved
outcomes with early epinephrine administration.23 25 Despite a lack
of subgroup analysis of outcomes in patients receiving IO medications
compared to IV medications, this study did not show any benefit of IO
access as a rescue vascular access method when attempts at IV
access failed.
Animal models have attempted to address the efficacy of drugs
administered through the IO route. Normotensive and shock animal
models have shown that the intraosseous route of medication
administration was comparable in effect with central and peripheral
intravenous routes for multiple medications including epinephrine,
sodium bicarbonate, and calcium chloride.26 Human studies have
shown no significant differences in pharmacokinetics observed
between IO and IV administration of morphine in normotensive
patients.11 However, bone marrow flow rates are greatly reduced
during cardiopulmonary resuscitation to about 20% 30% normal.27
Further animal studies have shown that during resuscitation after
hypovolemic cardiac arrest, bone marrow blood flow is nearly absent
after high-dose epinephrine injection, but was maintained after highdose vasopressin, which is no longer included in the ACLS protocols
for cardiac arrest resuscitation.28 Given that epinephrine is the initial
drug administered in cardiac arrest resuscitation, the low bone marrow
flow that ensues may prevent further resuscitative medications from
reaching the central circulation. This flow reduction could account for
the reduced rates of ROSC found in our study and in the literature.
Although there is paucity of recent literature, some studies have
identified slower drug transport rates to the inferior vena cava versus
superior vena cava in cardiac arrest.29 31 This may be related to the
lack of a pressure gradient between the inferior vena cava and right
atrium. The suggestion without studies comparing upper and lower
extremity IVs, that lower extremity vascular access, rather than IV vs
IO access may play a role in resuscitation rates.32
Animal models have also shown that proximal IO drug administration sites (humeral or sternal) more rapidly achieve maximal
therapeutic plasma concentrations than more distal IO sites (tibial).33
Additionally, in a cardiac arrest swine model, O’Sullivan et al. showed
that there was a significant delay in time to ROSC and a significant
difference in odds of ROSC when drugs were administered via the
tibial IO route compared to the sternal IO or IV routes. There was no
difference in odds of ROSC between the sternal IO route and IV route
of drug administration.34 Burgert et al. however showed no significant
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differences in ROSC between epinephrine administration via the
humeral IO, tibial IO, or IV route in an adult swine model of ventricular
fibrillation.35
It is possible that use of the proximal tibia IO insertion site is
suboptimal for the treatment of OHCA. The proximal tibia is far
removed from the central circulation, and has been observed to have
significantly lower flow rates and higher resistance to flow than the
humeral or sternal IO insertion sites.36,37 It is unknown whether use of
the sternal or humeral IO sites would have been associated with
different outcomes, although the prospect of improved flow rates
would appear to offer benefit. Given the conflicting data in animal
models with regards to equivalency of distal and proximal IO, it is
unclear if patients with humeral or sternal IO would have similar
outcomes to those with IV access. Future human studies are needed
to determine if the location of IO access is associated with different
outcomes in OHCA.

Limitations
Several limitations of our study are notable. First, our study included
only data on OHCA in the metropolitan Detroit area, which may limit
generalizability to patient populations in other geographic areas.
Second, our data set did not specify timing to first drug administration,
information on number of attempts for IV compared to IO access, and
whether drug administration was followed by fluid bolus or pressure
bags, which can affect drug distribution.13 Third, the route of vascular
access chosen for a given patient may not have been randomly
selected and was not standardized across EMS agencies. EMS
agencies in the three counties studied did not specify IO or IV access
as first or second line. Medics were provided the option to use either IO
or IV. Again, data on timing of access or number of attempts at access
were not available. Patients perceived to have difficult-to-obtain IVs
may have been selectively given IO access. Inability to obtain an IV
could be a surrogate marker of unaccounted comorbidities and
possibly unrecognized long downtime. While propensity score
matching may reduce the effect of potential selection bias in choice
of access on the main results of this study, residual confounding is
possible as data was incomplete on certain comorbidities such as end
stage renal disease and obesity. Fourth, outcomes could also be
affected by hospital interventions and post-ROSC care including
cardiac catheterization. Cardiac catheterization data was sparse
within our database and was therefore not included. Finally, our data
only includes patients who have received proximal tibial IO. Therefore,
our results cannot be generalized to patients receiving humeral or
sternal IO access in OHCA.

Conclusions
In this large sample of OHCA patients with a high proportion of IO
use for drug delivery, we found that reduced ROSC, worse
neurological function, and reduced rates of survival to hospital
discharge were associated with the use of IO compared to IV drug
administration. We observed that OHCA patients that receive
prehospital IO drug infusions also have characteristics that are
unfavorable to survival and may confound investigations into this
question. These results, along with those from other recent studies,
underscore the need for randomized controlled trials to properly
evaluate the relative efficacy of the IO routes of drug delivery for
OHCA resuscitation.
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